Lysosomal Storage Disease Articles & Analysis
6 news found
(Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators (STARs) identified with its proprietary computational discovery platform, today presented new pre-clinical data from its Gaucher Disease (GD) program. These results were highlighted in a late breaking abstract presentation at the ...
Capitalizing on significant advances in computational biology and drug discovery, the Company has applied its proprietary computational SEE-Tx® platform to generate its lead programs in GBA1 Parkinson’s disease, Gaucher disease as well as four additional programs to advance the treatment of lysosomal storage disorders. ...
Outeiro's major research interests are focused on the understanding of the molecular mechanisms which lead to neurodegeneration in diseases such as Parkinson's, Huntington's and Alzheimer's disease. Ricardo A. ...
"One of our Foundation's major goals is to find a disease-modifying therapy for HIV/AIDS," said Ken Rapkin, Program Officer of Campbell. ...
The company's lead program is for Parkinson's disease. Additional pipeline programs include other CNS disorders, such as neuro-HIV (supported by a grant awarded by The Campbell Foundation), Alzheimer's disease, GBM (brain cancer), ALS (Lou Gehrig's disease) and lysosomal storage diseases (LSDs), ...
The MCD Group report includes an in-depth profile of Lauren Sciences, providing a scientific description of the V-Smart™ technology and detailed information on its V-Smart™ therapeutic programs in central nervous system (CNS) diseases such as Parkinson's disease, neuro-HIV and brain cancer. "The inclusion of Lauren Sciences in the MCD Group report is ...